UBS Group’s Science 37 Holdings, Inc. Common Stock SNCE Stock Holding History

UBS Group’s Portfolio SNCE Stock Details SNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,835	Closed	-$36.5K	–	10331
2023 Q4	$36.5K	Buy	+6,835	New	+$42.1K	﹤0.01%	6729
2023 Q3	–	Sell	-75	Closed	-$319	–	10186
2023 Q2	$319	Sell	75 -927	-93%	-$5.25K	﹤0.01%	8311
2023 Q1	$5.65K	Buy	1,002 +450	+82%	+$3.42K	﹤0.01%	8007
2022 Q4	$4.64K	Buy	+552	New	+$10.8K	﹤0.01%	9303
2022 Q2	–	Sell	-2,007	Closed	-$215K	–	11232
2022 Q1	$215K	Buy	+2,007	New	+$314K	﹤0.01%	5296
2021 Q4	–	Sell	-156	Closed	-$31K	–	10911
2021 Q3	$31K	Buy	156 +76	+95%	+$15.2K	﹤0.01%	6728
2021 Q2	$16K	Buy	+80	New	+$16.2K	﹤0.01%	7598

UBS Group's SNCE Position: Q1 2024 in Review

UBS Group sold out of Science 37 Holdings, Inc. Common Stock (SNCE) in Q1 2024, closing a stake of 6,835 shares — an estimated $36.5K sold.

UBS Group first reported a position in SNCE in Q2 2021 and held it in 7 quarters. The position peaked at $215K in Q1 2022. 0 funds tracked by Wall St. Rank hold SNCE as of Q1 2024.

UBS Group reported no remaining Science 37 Holdings, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
UBS Group sold 6,835 Science 37 Holdings, Inc. Common Stock shares in Q1 2024, an estimated $36.5K.
UBS Group first reported a position in Science 37 Holdings, Inc. Common Stock in Q2 2021 and held it in 7 quarters.
UBS Group's Science 37 Holdings, Inc. Common Stock position peaked at $215K in Q1 2022.
0 funds tracked by Wall St. Rank held Science 37 Holdings, Inc. Common Stock as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.